The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
This report shows about half over the age of 65 say they have already received at least one dose of the vaccine or have scheduled an appointment to do so. It also examines how easy or difficult it has been for people to get an appointment and information about the vaccine, and where the public would most like to receive it.
This brief answers key questions about the U.S. monkeypox outbreak to date and identifies issues that may affect the response going forward.
Long COVID has been described as our “next national health disaster” and the “pandemic after the pandemic,” but we know little about how many people are affected, how long it will last for those affected, and how it could change employment and health coverage landscapes. This policy watch reviews what we know and outlines key questions to watch for regarding employment and coverage outcomes. We continue to follow the research on who is most at risk of long COVID and whether there are interventions that can reduce its incidence, length, or severity.
This analysis illustrates the potential total cost of Pfizer and Moderna COVID-19 vaccines, based on their publicly-announced expected prices, once they enter the U.S. commercial market. It compares the average price paid by the federal government for the COVID-19 bivalent boosters to the estimated average commercial prices across different scenarios.
This issue brief analyzes how the new CDC Public Health Infrastructure Grant (PHIG) workforce funding has been distributed across health departments in the U.S., and also jurisdictional plans for public health workforce hiring using funds from PHIG.
This analysis examines jurisdictional approaches to eligibility for monkeypox (MPX) vaccine. Overall, almost all jurisdictions have, at minimum, adopted the current approach laid out by the CDC. However, there is substantial variation in how eligibility is defined. Additionally, several jurisdictions lack clear criteria or information on who is eligible or where to get vaccinated. This may impact on who gets vaccinated, lead to geographic disparities, and raises potentially equity challenges.
According to a new KFF analysis assessing monkeypox (MPX) vaccine eligibility across the United States, people who are exposed or presumed exposed to MPX are generally eligible to get a vaccine across the country. However, eligibility varies across the United States for certain workers, including laboratory staff and others who might be at increased risk.
This analysis examines monkeypox (MPX) cases and vaccinations by race/ethnicity based on national data obtained from the Centers for Disease Control and Prevention (CDC). We find that while the current MPX outbreak in U.S. appears to be slowing down, disparities persist among Black and Hispanic people.
More than three years into the COVID-19 pandemic, about half (53%) the public says they would likely get an annual COVID-19 vaccine if offered similar to an annual flu shot, the latest KFF COVID-19 Vaccine Monitor finds. This includes about a third (32%) who would be “very likely” to do so.
A new KFF analysis finds that between 8 and 24 million people across the U.S. could be disenrolled from Medicaid during the unwinding of the program’s continuous enrollment provision. The estimates draw on data collected through KFF’s recent survey of state Medicaid and CHIP officials, conducted with the Georgetown University Center for Children and Families.
© 2025 KFF
